ScandiBio Therapeutics announced results from the study “Combined Metabolic Activators Reduces Liver Fat in Nonalcoholic Fatty Liver Disease” were published on Cell Press Sneak Peek, a…
ScandiBio Therapeutics has completed a Phase II study based on treatment of patients with COVID-19. Patients with mild-to-moderate COVID-19 experienced a 29% reduction in recovery time…
A review paper has been published in the journal iScience about the use of drug repositioning applications in treatment of COVID-19 patients. The rapid and global…
A review paper has been published in the journal Frontiers in Neuroscience discussing the use of AI-based systems biology approaches to understand the Host–Microbiome Interactions in…
The Board of Directors of ScandiBio Therapeutics has, in accordance with the issue authorization granted by the extraordinary general meeting on May 15, 2020, carried out…
A review paper has been published in the journal Drug Discovery Today discussing the use of systems biology approaches for studying neurodegenerative diseases including Alzheimer’s Disease…
ScandiBio Therapeutics has initiated a Phase II study in patients with COVID-19 using Combined Metabolic Cofactors Supplementation (CMCS) consisting of L-serine, N-acetyl-L-cysteine (NAC), nicotinamide riboside (NR),…
ScandiBio Therapeutics has initiated a Phase II study in patients with Alzheimer’s Disease (AD) and Parkinson’s Disease (PD) using Combined Metabolic Cofactors Supplementation (CMCS) consisting of…
ScandiBio Therapeutics has initiated a Phase II study in patients with Non-Alcoholic Fatty Liver Diseases (NAFLD) using Combined Metabolic Cofactors Supplementation (CMCS) consisting of L-serine, N-acetyl-L-cysteine…